Phase II study of inotuzumab ozogamicin in MRD+ B-ALL

Phase II study of inotuzumab ozogamicin in MRD+ B-ALL

A phase II study of blinatumomab for the treatment of MRD-positive B-cell acute lymphoblastic le...Подробнее

A phase II study of blinatumomab for the treatment of MRD-positive B-cell acute lymphoblastic le...

Inotuzumab ozogamicin for MRD-positive B-ALLПодробнее

Inotuzumab ozogamicin for MRD-positive B-ALL

Inotuzumab ozogamicin for the treatment of elderly acute lymphoblastic leukemiaПодробнее

Inotuzumab ozogamicin for the treatment of elderly acute lymphoblastic leukemia

Inotuzumab ozogamicin and chemotherapy with or without blinatumomab in Philadelphia chromosone-n...Подробнее

Inotuzumab ozogamicin and chemotherapy with or without blinatumomab in Philadelphia chromosone-n...

A Phase II adaptive study of dasatinib and inotuzumab-based induction for newly diagnosed Ph+ ALLПодробнее

A Phase II adaptive study of dasatinib and inotuzumab-based induction for newly diagnosed Ph+ ALL

Hyper-CVAD with blinatumomab and inotuzumab ozogamicin for patients with newly diagnosed Ph- B-ALLПодробнее

Hyper-CVAD with blinatumomab and inotuzumab ozogamicin for patients with newly diagnosed Ph- B-ALL

Inotuzumab ozogamicin & venetoclax in the treatment of B-ALL: findings from a Phase I trialПодробнее

Inotuzumab ozogamicin & venetoclax in the treatment of B-ALL: findings from a Phase I trial

Phase II trial of inotuzumab ozogamicin to treat MRD+ B-ALLПодробнее

Phase II trial of inotuzumab ozogamicin to treat MRD+ B-ALL

Inotuzumab ozogamicin for treating pediatric R/R ALLПодробнее

Inotuzumab ozogamicin for treating pediatric R/R ALL

Inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic leukaemia: results of ...Подробнее

Inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic leukaemia: results of ...

Dr. DeAngelo on Inotuzumab Ozogamicin for Relapsed/Refractory ALLПодробнее

Dr. DeAngelo on Inotuzumab Ozogamicin for Relapsed/Refractory ALL

What is the role of inotuzumab ozogamicin in ALLПодробнее

What is the role of inotuzumab ozogamicin in ALL

Emerging novel approaches for ALL: inotuzumab ozogamicinПодробнее

Emerging novel approaches for ALL: inotuzumab ozogamicin

The addition of inotuzumab ozogamicin to hyper-CVAD + blinatumomab in patients with B-ALLПодробнее

The addition of inotuzumab ozogamicin to hyper-CVAD + blinatumomab in patients with B-ALL

Blinatumomab vs inotuzumab ozogamicin for ALLПодробнее

Blinatumomab vs inotuzumab ozogamicin for ALL

Choosing between inotuzumab ozogamicin and blinatumomab in patients with R/R ALLПодробнее

Choosing between inotuzumab ozogamicin and blinatumomab in patients with R/R ALL

Phase II study shows blinatumomab achieves minimal residual disease response in ALLПодробнее

Phase II study shows blinatumomab achieves minimal residual disease response in ALL

Relapsed/Refractory ALL: Inotuzumab OzogamicinПодробнее

Relapsed/Refractory ALL: Inotuzumab Ozogamicin

Updated results of hyper-CVAD and blinatumomab +/- inotuzumab ozogamicin in newly-diagnosed B-ALLПодробнее

Updated results of hyper-CVAD and blinatumomab +/- inotuzumab ozogamicin in newly-diagnosed B-ALL